Search details
1.
Phase 1b study of pan-AKT inhibitor vevorisertib alone or with paclitaxel or fulvestrant in PIK3CA/AKT/PTEN-mutated advanced solid tumors.
Cancer
; 129(12): 1919-1929, 2023 06 15.
Article
in English
| MEDLINE | ID: mdl-36970876
2.
Cannabis use among adults undergoing cancer treatment.
Cancer
; 129(21): 3498-3508, 2023 11 01.
Article
in English
| MEDLINE | ID: mdl-37354093
3.
Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma.
J Hepatol
; 66(3): 545-551, 2017 03.
Article
in English
| MEDLINE | ID: mdl-27816492
4.
Earlier presentation and application of curative treatments in hepatocellular carcinoma.
Hepatology
; 60(5): 1637-44, 2014 Nov.
Article
in English
| MEDLINE | ID: mdl-24996116
5.
First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors.
Cancer Res Commun
; 4(4): 1100-1110, 2024 Apr 18.
Article
in English
| MEDLINE | ID: mdl-38551394
6.
A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinoma.
JHEP Rep
; 6(2): 100982, 2024 Feb.
Article
in English
| MEDLINE | ID: mdl-38274490
7.
First-in-human Study of AZD5153, A Small-molecule Inhibitor of Bromodomain Protein 4, in Patients with Relapsed/Refractory Malignant Solid Tumors and Lymphoma.
Mol Cancer Ther
; 22(10): 1154-1165, 2023 10 02.
Article
in English
| MEDLINE | ID: mdl-37486983
8.
Avelumab Plus Talazoparib in Patients With BRCA1/2- or ATM-Altered Advanced Solid Tumors: Results From JAVELIN BRCA/ATM, an Open-Label, Multicenter, Phase 2b, Tumor-Agnostic Trial.
JAMA Oncol
; 9(1): 29-39, 2023 01 01.
Article
in English
| MEDLINE | ID: mdl-36394867
9.
The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial.
Nat Med
; 29(11): 2814-2824, 2023 Nov.
Article
in English
| MEDLINE | ID: mdl-37857711
10.
A Phase 1a/b Open-Label, Dose-Escalation Study of Etigilimab Alone or in Combination with Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumors.
Clin Cancer Res
; 28(5): 882-892, 2022 Mar 01.
Article
in English
| MEDLINE | ID: mdl-34844977
11.
Reversible HER2 antibody-drug conjugate-induced ocular toxicity.
Can J Ophthalmol
; 57(2): 118-126, 2022 04.
Article
in English
| MEDLINE | ID: mdl-33727105
12.
Antiangiogenic agents in combination with chemotherapy in patients with advanced non-small cell lung cancer.
Cancer Invest
; 29(4): 325-37, 2011 May.
Article
in English
| MEDLINE | ID: mdl-21469981
13.
Preclinical Evaluation and Phase Ib Study of Prexasertib, a CHK1 Inhibitor, and Samotolisib (LY3023414), a Dual PI3K/mTOR Inhibitor.
Clin Cancer Res
; 27(7): 1864-1874, 2021 04 01.
Article
in English
| MEDLINE | ID: mdl-33495309
14.
A Phase 1b Trial of Prexasertib in Combination with Standard-of-Care Agents in Advanced or Metastatic Cancer.
Target Oncol
; 16(5): 569-589, 2021 09.
Article
in English
| MEDLINE | ID: mdl-34559360
15.
Phase I and Preliminary Phase II Study of TRC105 in Combination with Sorafenib in Hepatocellular Carcinoma.
Clin Cancer Res
; 23(16): 4633-4641, 2017 Aug 15.
Article
in English
| MEDLINE | ID: mdl-28465443
16.
Identification of active chemotherapy regimens in advanced biliary tract carcinoma: a review of chemotherapy trials in the past two decades.
Hepat Oncol
; 2(1): 39-50, 2015 Jan 01.
Article
in English
| MEDLINE | ID: mdl-25685318
17.
Hepatocellular carcinoma and immune therapy, from a clinical perspective; where are we?
Hepat Oncol
; 3(3): 183-185, 2016 Aug.
Article
in English
| MEDLINE | ID: mdl-30191038
Results
1 -
17
de 17
1
Next >
>>